Fig. 1
From: CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients
The metabolomic characteristics of the screening set. a Study design including untargeted plasma metabolomics, lipidomic and GEP analysis. b Typical chromatograms of TIC in plasma samples from CRS group (containing participants with CRS within the first week post-infusion and without CRS at day 30 (D30) post-infusion). c Score plot of PCA based on the data of ESI+ mode from CRS group. d Score plot of OPLS-DA based on the data of ESI+ mode from CRS group. e Volcano plot based on the data of ESI+ mode from CRS group. f Score plot of PCA based on the data of ESI+ mode from comparative efficacy group (containing participants in remission (R) and non-remission (NR) at day 30 after infusion). g Score plot of OPLS-DA based on the data of ESI+ mode from comparative efficacy group. h Volcano plot based on the data of ESI+ mode from comparative efficacy group. i Heatmap showed 5 differential metabolites identified from the comparison of CRS vs D30. j Heatmap showed 7 differential metabolites identified from the comparison of R vs NR. k The changes of GPC level in CRS group. l–m The changes of LPC(16:0) and palmitoylcarnitine levels in comparative efficacy group. (*p < 0.05, **p < 0.01)